Nexus Biopharma Inc. (fka NEXS)

[TORO]

Nexus BioPharma, Inc. Expands Intellectual Property Scope

MONTCLAIR, N.J., Sept. 12, 2016 /PRNewswire/ -- Nexus BioPharma, Inc., (OTC-BB: NEXS), a company specializing in the development of a weight loss drug therapy, announced today that it has filed a New International Patent Application (PCT/US2016/050776) entitled "Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors." The application covers composition of matter and methods of use for specific compounds in a number of chemical structure families for the treatment of a variety of conditions including weight loss, symptoms of type 2 diabetes, neurodegenerative disease including Alzheimer's Disease, and the symptoms of ageing.

Warren C. Lau, the company's President and CEO, stated "This patent filing, when issued, provides important additional and very specific coverage to the company's licensed intellectual property position. It greatly expands our range of opportunities and markets."